Proteus Biomedical

By Brian Dolan 01:28 pm August 12, 2010
The United Kingdom's National Health Service plans to begin piloting Proteus Biomedical's "smart pills" this month to help curb health costs due to medication non-adherence among heart failure patients, according to a report in the Financial Times. The Royal Berkshire and Imperial College healthcare trusts are currently looking for 40 patients for the clinical trial, which will last four months....
By Brian Dolan 04:15 am August 2, 2010
To date, WellDoc's DiabetesManager is one of the few mobile health apps to have gone through an RCT. The United States Food and Drug Administration (FDA) has granted WellDoc 510(k) clearance to market its WellDoc DiabetesManager System to care providers and adult patients with type 2 diabetes. Next: WellDoc plans to commercially launch the WellDoc DiabetesManager System in early 2011. Five years...
By Brian Dolan 05:07 am July 31, 2010
AirStrip Technologies, makers of AirStripOB, on of the very first FDA approved medical applications in Apple's AppStore, today announced that the US Food and Drug Administration (FDA) had cleared its AirStrip Remote Patient Monitoring solution (RPM), which includes AirStrip RPM Critical Care and AirStrip RPM Cardiology. The clearance significantly expands AirStrip's suite of applications. Is it...
By Brian Dolan 09:46 am May 25, 2010
Zucker Hillside Hospital in Glen Oaks, New York is working with Proteus Biomedical to pilot the "intelligent medicine" company's edible sensor for certain mental illnesses, according to a report from Scientific American. "We're interested in determining patients' sleep patterns," John Kane, head of schizophrenia research at Zucker Hillside Hospital in Glen Oaks, N.Y. Kane. "For certain mental...
By Brian Dolan 01:15 am April 22, 2010
April showers, right? This week in mobile health news brings what appears to be the departure of a company MobiHealthNews has tracked since we published our first issue: AllOne Mobile (AOM). AOM and its partner Diversinet have been in court for the past few months discussing the appropriate breakup fee to dissolve their five-year agreement, which only made it to year two. Diversinet appears ready...
By Brian Dolan 08:45 am April 21, 2010
The FDA announced today that it has cleared Proteus Biomedical's wireless, adhesive sensor technology Raisin, which can track and record a patient's heart rate, physical activity, body position and other biometrics. Raisin then transmits the data via Bluetooth to a PC or mobile device. Proteus explains that the Raisin device is worn just like a bandaid. Raisin, however, is just one part of the...
By Brian Dolan 09:05 am February 24, 2010
We attended the TEDMED event this past October in San Diego, because it included a number of speakers discussing wireless health innovations: West Wireless Health Institute's Dr. Eric Topol, NeuroVigil's Dr. Phillip Low, Proteus Biomedical's Andrew Thompson as well as speakers from Intel, Qualcomm and more. TEDMED's organizers recently posted a video documenting Dr. Topol's presentation at the...
By Brian Dolan 12:35 am January 21, 2010
It's a widely known statistic that between one-third and one-half of patients in the U.S. do not take their medications as instructed, which leads to poorer health, more frequent hospitalization, a higher risk of death and up to $290 billion each year in increased medical costs. Stacked against that figure, Novartis' recent $24 million investment in intelligent medicine / medication adherence...
By Brian Dolan 03:23 am January 19, 2010
According to a report in the Economist, pharmaceuticals company Novartis' $24 million investment in intelligent medicine startup Proteus Biomedical may be just as important in the long run as Novartis' $50 billion takeover of eye-care firm, Alcon. Proteus Biomedical's venture capital round actually brought in $25.4 million, which makes us wonder if the difference came from an additional...
By Brian Dolan 03:47 am January 12, 2010
Pharmaceutical giant Novartis announced that would invest $24M in upfront cash and equity as part of an exclusive worldwide agreement for the pharma company to license Proteus Biomedical's sensing technology for organ transplantation. (That must be the kind of exclusive deal Novartis had in mind when the two companies announced their collaboration on a pilot last year.) As part of the deal,...